Multiple Infliximab Biosimilar Switches: Results Following A Nationwide Switch From Originator Infliximab To Biosimilar Ct-P13, And Subsequently To Biosimilar Gp1111, In Real-World Patients With Inflammatory Arthritis Followed In The Danish Danbio Registry
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要